리가켐, 노바락 'ADC 항체 공동연구' 계약 일부 해지

Ligand Chemogenomics' partial termination of its ADC antibody partnership with NovaRock Biotherapeutics reflects a critical shift in biotech R&D strategy, where companies increasingly prioritize portfolio optimization over broad collaboration. This move highlights how global competition and market viability assessments now drive partnership decisions, pushing companies to concentrate resources on the most promising candidates. For the biotech sector, such strategic consolidation signals a maturation phase where efficient capital allocation and selective focus are becoming competitive advantages.